Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial (Q34645665)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial |
scientific article |
Statements
1 reference
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial (English)
1 reference
Patrick Schöffski
1 reference
Margaret von Mehren
1 reference
Hans Gelderblom
1 reference
Peter Hohenberger
1 reference
George D Demetri
1 reference
Peter Reichardt
1 reference
Giuseppe Badalamenti
1 reference
Martin Blackstein
1 reference
Toshirou Nishida
1 reference
Christian Kappeler
1 reference
Iris Kuss
1 reference
Dirk Laurent
1 reference
Yoon-Koo Kang
1 reference
Sebastian Bauer
1 reference
Binh Bui Nguyen
1 reference
Jianming Xu
1 reference
John Chung
1 reference
GRID study investigators
1 reference
22 November 2012
1 reference
1 reference
381
1 reference
9863
1 reference
295-302
1 reference
Identifiers
1 reference
1 reference
1 reference